Intravenous MELAtonin for Preventing Agitation and Emergence Delirium in children. The MELA-PAED trial: a randomized, double-blind, placebo-controlled clinical trial.

Status

Suspended

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517592-20-00

Acronym

20211125

Enrollment

676

Registered

2024-11-11

Start date

2025-01-10

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence delirium

Brief summary

Emergence agitation

Detailed description

Opioid consumption, Non-serious adverse events

Interventions

DRUGNatriumklorid Fresenius Kabi 9 mg/ml

DRUGMelatonin

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Emergence agitation	—

Secondary

Measure	Time frame
Opioid consumption, Non-serious adverse events	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026